The effect observation of Huoxue Huayu Decoction combined with methotrexate on ectopic pregnancy

doi:10.11958/20212481

Abstract

Abstract:

Objective To explore and analyze the effect of Huoxue Huayu Decoction combined with methotrexate in the treatment of ectopic pregnancy and its effect on the level of peripheral blood miR-323-3p. Methods A total of 106 patients with ectopic pregnancy were selected and divided into the observation group (n=54) and the control group (n=52) according to the random number table method. The control group was given methotrexate combined with mifetil. The observation group was additionally treated with Huoxue Huayu Decoction on the basis of the treatment of the control group. The recovery time of blood -human chorionic gonadotropin (HCG) level, the time of mass absorption, the complete patency rate of fallopian tubes after treatment and changes of serum VEGF and miR-323-3p were compared between the two groups. Results Compared with the control group, the success rate of conservative treatment was increased in the observation group (92.59% vs. 78.85%), and the time for blood β-HCG to return to normal and the time for mass absorption were shortened (P<0.05). Compared with the control group, the complete patency rate of the affected fallopian tube increased significantly after 3 months of treatment in the observation group (52.00% vs. 29.27%, P<0.05). Compared with before treatment, the relative expressions of serum VEGF and mir-323-3p decreased significantly 1 month after treatment in the two groups (P<0.05). Compared with the control group, the relative expressions of serum VEGF and miR-323-3p and adverse reactions decreased significantly 1 month after treatment in the observation group (P<0.05). Conclusion Huoxue Huayu Decoction combined with methotrexate can effectively improve the success rate of conservative treatment for patients with ectopic pregnancy, which helps the absorption of mass after treatment and patency of fallopian tubes, and can effectively reduce serum levels of VEGF and miR-323-3p in patients, indicating high drug safety.

Key words: pregnancy,ectopic, TCM WM therapy, Methotrexate, huoxue huayu decoction, miR-323-3p in peripheral blood, VEGF

CLC Number:

R714.22

Figures/Tables 6

References 19

[1]	蒋晶, 杨文香, 柴芝红. 阴道超声联合血清PAPP-A、AMH水平在异位妊娠早期的诊断价值[J]. 中国妇幼保健, 2020, 35(6):1155-1158.
	YANG J, YANG W X, CHAI Z H. Value of vaginal ultrasound combined with serum PAPP-A and AMH levels in early diagnosis of ectopic pregnancy[J]. Maternal & Child Health Care of China, 2020, 35(6):1155-1158. doi: 10.19829/j.zgfybj.issn.1001-4411.2020.06.060.
[2]	杨振光. 异位妊娠诊断中腹部B超的应用[J]. 中国药物与临床, 2020, 20(4):531-533.
	Yang Z G. Application of abdominal ultrasound in diagnosis of ectopic pregnancy[J]. Chinese Remedies& Clinics, 2020, 20(4):531-533. doi: 10.11655/zgywylc2020.04.013.
[3]	HASANI S, MIRGHAFOURVAND M, ESMAEILPOUR K, et al. The effect of counseling based on health promotion awareness on mental health and self-esteem in women with ectopic pregnancy: A randomized controlled clinical trial[J]. J Matern Fetal Neonatal Med, 2021, 34(11):1687-1694. doi: 10.1080/14767058.2019.1644314.
[4]	向健, 王俊. 外周血miR-323-3p在异位妊娠早期诊断中的作用[J]. 现代医学, 2019, 47(8):900-904.
	XIANG J, WANG J. Diagnosis value of miR-323-ep in early ectopic pregnancy[J]. Modern Medical Journal, 2019, 47(8):900-904. doi: 10.3969/j.issn.1671-7562.2019.08.004.
[5]	张磊, 梁小梅, 黎秋怡, 等. 米非司酮结合中药汤剂+艾灸治疗早期异位妊娠的临床效果[J]. 内蒙古中医药, 2020, 39(2):24-25.
	ZHANG L, LIANG X M, LI Q Y, et al. Clinical effect of mifepristone combined with traditional Chinese medicine decoction+moxibustion in the treatment of early ectopic pregnancy[J]. Nei Mongol Journal of Traditional Chinese Medicine, 2020, 39(2):24-25.
[6]	MORSE A N, SI W, QIN S, et al. Optimal use of peri-operative human chorionic gonadotrophin concentrations to identify persistent ectopic pregnancy after laparoscopic salpingostomy:a retrospective cohort study[J]. Reprod Biomed Online, 2018, 36(3):361-368. doi: 10.1016/j.rbmo.2017.12.006.
[7]	王秋凤, 曾艳花, 唐晓霞. 不同甲氨蝶呤用药方案联合米非司酮治疗异位妊娠疗效观察[J]. 海南医学, 2017, 28(22):3736-3738.
	WANG Q F, ZENG Y H, TANG X X. Clinical efficacy of different regimens of methotrexate combined with mifepristone in the treatment of ectopic pregnancy[J]. Hainan Medical Journal, 2017, 28(22):3736-3738. doi: 10.3969/j.issn.1003-6350. 2017.22.042.
[8]	袁烁, 沈秋娴, 卢如玲, 等. 留置宫内节育器与异位妊娠发生关系的Meta分析[J]. 中国医药导报, 2019, 16(30):93-96.
	YUAN S, SHENG Q X, LU R L, et al. Relationship between intrauterine device and incidence of ectopic pregnancy:A Meta-analysis[J]. China Medical Herald, 2019, 16(30):93-96.
[9]	BARNHART K T, HANSEN K R, STEPHENSON M D, et al. Effect of an active vs expectant management strategy on successful resolution of pregnancy among patients with a persisting pregnancy of unknown location: The ACT or NOT randomized clinical trial[J]. JAMA, 2021, 326(5):390-400. doi: 10.1001/jama.2021.10767.
[10]	SCHREIBER C A, CREININ M D, ATRIO J, et al. Mifepristone pretreatment for the medical management of early pregnancy loss[J]. N Engl J Med, 2018, 378(23): 2161-2170. doi: 10.1056/NEJMoa1715726.
[11]	司红梅, 于旭东, 商建伟, 等. 基于网络药理学探讨威灵仙-天花粉药对抗癌的作用机制[J]. 中国实验方剂学杂志, 2021, 27(5):182-190.
	SI H M, YU X D, SHANG J W, et al. Anti-cancer Mechanism of "Clematis Radix et Rhizoma-Trichosanthis Radix" Based on Network Pharmacology[J]. Chinese Journal of Experimental Traditional Medical Formulae, 2021, 27(5):182-190. doi: 10.13422/jcnki.syfjx.20210215.
[12]	金利思, 翁金月, 郑京胜, 等. 基于网络药理学探讨莪术抗血栓的作用机理[J]. 中国中医药科技, 2020, 27(2):224-226,239.
	JIN L S, WEN J Y, ZHENG J S, et al. Mechanism of ezhu(Curumae Rhizoma) in treating thrombosis based on network pharmacology[J]. Chinese Journal of Traditional Medical Science and Technology, 2020, 27(2):224-226,239.
[13]	宁迪敏, 田莎, 郭垠梅, 等. 蜈蚣抗肝癌的临床应用及药理研究[J]. 中医肿瘤学杂志, 2020, 2(1):39-41.
	SONG D M, TIAN S, GUO G M, et al. Clinical application and pharmacological research of chinese medicine scolopendra on anti-hepatocarcinoma[J]. Journal of Oncology in Chinese Medicine, 2020, 2(1):39-41. doi: 10.19811/j.cnki.ISSN2096-6628.2020.01.010.
[14]	李珊, 吕明, 杨剑, 等. 活性筛选和网络分析初步阐释常用活血化瘀中药抗血小板黏附的分子机制[J]. 药学学报, 2019, 54(11):1990-1999.
	LI S, LU M, YANG J, et al. Exploring molecular mechanisms of anti-platelet adhesion of Chinese medicine for promoting blood circulation and removing blood stasis by activity screen and network analysis[J]. Acta Pharmaceutica Sinica, 2019, 54(11):1990-1999. doi: 10.16438/j.0513-4870.2019-0297.
[15]	马海燕, 陈素华. 复方益母草胶囊治疗血瘀型产后恶露不绝的疗效观察[J]. 中国中医药科技, 2020, 27(3):473-474.
	MA H Y, CHEN S H. Observation on the curative effect of compound motherwort capsule in the treatment of blood stasis type postpartum lochia[J]. Chinese Journal of Traditional Medical Science and Technology, 2020, 27(3):473-474.
[16]	FLYNN A N, ROE A H, KOELPER N, et al. Timing and efficacy of mifepristone pretreatment for medical management of early pregnancy loss[J]. Contraception, 2021, 103(6):404-407. doi: 10.1016/j.contraception.2021.01.007.
[17]	王泽华, 于皓, 程晓燕, 等. 复方紫草汤联合甲氨蝶呤保守治疗异位妊娠的疗效观察及对患者妊娠结局的影响[J]. 中国中医药科技, 2020, 27(3):452-454.
	WANG Z H, YU H, CHENG X Y, et al. Observation of curative effect of Fufang Zicao Decoction combined with methotrexate in conservative treatment of ectopic pregnancy and its effect on pregnancy outcome of patients[J]. Chinese Journal of Traditional Medical Science and Technology, 2020, 27(3):452-454.
[18]	施锦梅, 朱茵. 补肾活血化瘀中药联合腹腔镜手术对子宫内膜异位症不孕患者性激素、氧化应激及生育情况的影响[J]. 中国妇幼保健, 2019, 34(24):5740-5742.
	SHI J M, ZHU Y. Effects of traditional Chinese medicine for tonifying kidney and promoting blood circulation and removing blood stasis combined with laparoscopic surgery on sex hormones,oxidative stress and fertility in infertile patients with endometriosis[J]. Maternal & Child Health Care of China, 2019, 34(24):5740-5742. doi: 10.7620/zgfybj.j.issn.1001-4411.2019.24.59.
[19]	王伟群, 梁伟翔, 张华, 等. 经阴道彩色多普勒超声检查结合腹部推挤在诊断早期异位妊娠中的应用价值[J]. 实用医学杂志, 2012, 28(21):3557-3559.
	WANG W Q, LIANG W X, ZHANG X, et al. The value of transvaginal color Doppler combinated with abdominal palpation in the diagnosis of early ectopic pregnancy[J]. The Journal of Practical Medicine, 2012, 28(21):3557-3559. doi: 10.3969/j.issn.1006-5725.2012. 21.021.

组别	n	年龄（岁）	体质量（kg）	停经时间（d）	妊娠次数（次）	β-HCG（U/L）	包块直径（cm）
观察组	54	29.73±5.31	56.27±7.21	45.28±9.04	1.79±0.52	142.48±38.94	3.42±1.30
对照组	52	30.16±6.44	55.92±6.93	44.72±8.08	1.71±0.46	149.85±41.28	3.71±1.47
t		0.376	0.255	0.340	0.710	0.946	1.077

组别	n	年龄（岁）	体质量（kg）	停经时间（d）	妊娠次数（次）	β-HCG（U/L）	包块直径（cm）
观察组	54	29.73±5.31	56.27±7.21	45.28±9.04	1.79±0.52	142.48±38.94	3.42±1.30
对照组	52	30.16±6.44	55.92±6.93	44.72±8.08	1.71±0.46	149.85±41.28	3.71±1.47
t		0.376	0.255	0.340	0.710	0.946	1.077

组别	n	血β-HCG恢复正常时间	包块吸收时间
对照组	41	21.08±7.22	48.79±15.36
观察组	50	16.94±6.39	40.26±12.35
χ²		2.898^＊＊	2.942^＊＊

组别	n	血β-HCG恢复正常时间	包块吸收时间
对照组	41	21.08±7.22	48.79±15.36
观察组	50	16.94±6.39	40.26±12.35
χ²		2.898^＊＊	2.942^＊＊

组别	n	完全通畅	基本通畅	不通畅
对照组	41	12（29.27）	12（29.27）	17（41.46）
观察组	50	26（52.00）	16（32.00）	8（16.00）
χ²		4.786^＊	0.079	7.331^＊＊